secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001193125-23-266741
Event type: earnings
Sentiment:  negative
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen Q3 revenue $141.2M (-30% YoY); narrows FY2023 outlook, sees order recovery
--------------------------------------------------------------------------------

- Total revenue $141.2M, base business $140.1M; GAAP EPS $0.32, adjusted EPS $0.23.
- Book-to-bill ratio of 1.07; orders strengthened, especially from Pharma customers.
- Narrows FY2023 revenue guidance to $635-645M (prev. $635-665M); lowers adj. operating margin to 15-16%.
- Restructuring charges of $24M in operating income; acquired Metenova AB on Oct 2 for $164M cash + $9M equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312523266741/0001193125-23-266741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312523266741/d510261d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-266741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer